Business Wire (Free subscription) | 10/09/2008
EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq:ADLR) announced today the appointment of John M. Limongelli, Esq., as senior vice president, general counsel and secretary. Mr.
The Pittsburgh Business Times (Free subscription) | 02/09/2008
GlaxoSmithKline has returned to Adolor Corp. the worldwide rights related to the development of the Entereg drug for chronic opioid bowel dysfunction. (ADLR) (GSK)
The Philadelphia Business Journal (Free subscription) | 02/09/2008
GlaxoSmithKline has returned to Adolor Corp. the worldwide rights related to the development of the Entereg drug for chronic opioid bowel dysfunction. (ADLR) (GSK)
Red Orbit (Free subscription) | 02/09/2008
Adolor Corporation (Nasdaq: ADLR) announced today that GlaxoSmithKline (GSK) has returned to Adolor worldwide rights related to Entereg(R) (alvimopan) for chronic opioid bowel dysfunction (OBD).
Business Wire (Free subscription) | 02/09/2008
EXTON, Pa.--(BUSINESS WIRE)--Adolor Corporation (Nasdaq: ADLR) announced today that GlaxoSmithKline (GSK) has returned to Adolor worldwide rights related to Entereg®
DeepMarket Stock Market Blog (Free subscription) | 21/09/2008
Seasonal Patterns found for the following stocks: Adolor Corporation (ADLR) over the next 9 trading days. Look at the seasonal patterns for Adolor Corporation in context. ChinaNatural Resources (CHNR) over the next 9 trading days. Look at the seasonal patterns for ChinaNatural Resources in context. Carolina Bk Hldgs Grnsbro Nc (CLBH) over the next 4 trading [...]
Fiercebiotech (Free subscription) | 03/09/2008
> GSK has returned the worldwide rights to Entereg as a therapy for chronic opioid bowel dysfunction to Adolor as it scales back on its commitment to the drug. Glaxo is retaining the rights to the drug as a therapy for post operative ileus. Adolor plans to pursue the work on chronic opioid bowel dysfunction. Release > Shares of Spain's Almirall dived on the news that its key lung disease...
24/7 Wall St. (Free subscription) | 03/09/2008
These are some of the top analyst downgrades and negative calls we are seeing this Wednesday morning: Adolor (ADLR) Cut to Neutral at Piper Jaffray. Allscripts... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Nature (Free subscription) | 01/09/2008
In May 2008, alvimopan (Entereg; Adolor/GlaxoSmithKline), a peripherally acting μ-opioid receptor antagonist, was approved by the US FDA to accelerate the time to gastrointestinal recovery following bowel resection surgery. It is the first pharmacotherapy to be approved for this application.
The Triangle Business Journal (Free subscription) | 02/09/2008
has scaled back its development agreement for the gastrointestinal drug Entereg.The company no longer will work with its collaborator, Pennsylvania-based , to develop Entereg as a treatment for chronic opioid bowel dysfunction, or COBD. COBD is the scientific name for gastrointestinal problems caused by the long-term use of painkillers such as morphine.GlaxoSmithKline (NYSE: GSK) and Adolor...
Alertnet (Free subscription) | 18/08/2008
... developing treatments for the condition.Entereg or alvimopan, from GlaxoSmithKline Plc
